Publications
- Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy2020 | Faculty of Medicine in Hradec Králové
- CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate2019 | Faculty of Medicine in Hradec Králové
- Monitoring of Lymphocyte Populations During Treatment with Interferon--1b to Predict Multiple Sclerosis Disability Progression2019 | Faculty of Medicine in Hradec Králové
- Alemtuzumab treatment in multiple slerosis: real clinical experience2019 | Faculty of Medicine in Hradec Králové
- Lymphocyte populations and their change during five-year glatiramer acetate treatment2018 | Faculty of Medicine in Hradec Králové
- Lymphocytes in the treatment with interferon beta-1 b2017 | Faculty of Medicine in Hradec Králové
- Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries2023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 20212023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis2023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Second Faculty of Medicine
- The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer's disease2023 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
Loading network view...